Immunicum secures financing to begin allogeneic cell-based cancer vaccine trial
This article was originally published in Scrip
Executive Summary
Immunicum has been given the go ahead by Sweden's regulator to begin the first clinical trial of its dendritic cell-based cancer vaccine in patients with kidney cancer. The company also reported that it has secured 'substantial' financing to complete the trial.